NEW YORK, Nov. 18 (GenomeWeb News) - Agilent Technologies yesterday posted an eight percent year-over-year increase in revenues for its Life Science and Chemical Analysis business unit for its fourth fiscal quarter ended Oct. 31, 2003.
The Life Science and Chemical Analysis segment, which includes capillary electrophoresis, GC and GC/MS, LC and LC/MS, informatics, microarrays, lab-on-a-chip, and other products and services, brought in $331 million during the quarter, compared to $298 million in the year-ago period. The segment accounted for 19 percent of the company's total quarterly revenues of $1.68 billion, which includes revenues from its Test and Measurement, Semiconductor Products, and Automated Test business units.
Aglient said revenues for the Life Science and Chemical Analysis segment were at record levels for the quarter. The segment posted an operating profit of $53 million for the quarter, up from $43 million in the year-ago period.
Agilent spent $221 million in R&D across all four of its business units for the fourth quarter, down from $322 million in the year-ago period.
The company reported overall net income of $13 million for the quarter, compared to a loss of $236 million for the same period last year.
Agilent ended the quarter with around $1.6 billion in cash and equivalents.